Evidence map›Paper›PMID 40601049›Full record

ArticleCancer chemotherapy and pharmacology2025

Pazopanib and antacids: insights from the WHO pharmacovigilance database.

Kazuki Nishida, Yao Liang, Osamu Maeda, Angélique Da Silva, Yuichi Ando, Basile Chrétien

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kazuki NishidaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan. nishida.kazuki.2z@kyoto-u.ac.jp.ORCID http://orcid.org/0000-0003-0367-8557
Yao LiangDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.ORCID http://orcid.org/0009-0005-2365-1513
Osamu MaedaDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4700-6541
Angélique Da SilvaDepartment of Pharmacology, Caen University Hospital, Caen, 14000, France.ORCID http://orcid.org/0000-0002-8193-5144
Yuichi AndoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0002-6849-2297
Basile ChrétienDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0002-7483-2489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pazopanib, a multi-targeted tyrosine kinase inhibitor, is used for advanced renal cell carcinoma and soft tissue sarcoma. However, it is associated with dose-dependent adverse events (AEs), including hypertension, and gastrointestinal issues. Antacids like proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are often co-administered, raising concerns about potential drug interactions. Pazopanib's solubility and absorption are pH-dependent, with increased gastric pH potentially reducing its bioavailability. In this study, we analyzed VigiBase

Indexed as

AntacidsPyrimidinesSulfonamidesAgedDatabases, FactualDrug InteractionsFemaleHistamine H2 AntagonistsHumansIndazolesMaleMiddle AgedPharmacovigilanceProton Pump InhibitorsAntacidsHistamine H2 AntagonistsIndazolespazopanibProton Pump InhibitorsPyrimidinesSulfonamidesAdverse eventsDrug-drug interactionsH2RAsPazopanibPPIsVigiBase

Identifiers

PMID40601049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.